Research Article
Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application
Table 3
The stability of enasidenib in rat plasma (n = 6).
| | Compounds | Spiked (ng/mL) | Room temperature, 12 h | Autosampler 4°C, 12 h | Three freeze-thaw | −20°C, 4 weeks | | RSD (%) | RE (%) | RSD (%) | RE (%) | RSD (%) | RE (%) | RSD (%) | RE (%) |
| | Enasidenib | 2.5 | 4.51 | −0.76 | 5.94 | −3.45 | 6.79 | 0.47 | 8.69 | −1.94 | | 400 | 5.15 | −0.55 | 3.35 | 1.96 | 5.48 | 0.76 | 4.08 | 1.07 | | 800 | 2.24 | 2.73 | 2.48 | 3.75 | 1.35 | 2.38 | 2.94 | 1.79 |
|
|
